Fyodor (which means “Divine Gift") delivers simple innovative solutions to major global health problems. Our innovative technologies advance patient-centric diagnostic capabilities that help expand access to appropriate care in home and point-of-care settings.
Many years ago, a woman had to go to a doctor’s clinic or clinical laboratory to test if she was pregnant, and diabetes patients regularly to a lab to check their blood sugar. Today, no more, thanks to the empowering ability for home testing.
Our flagship product is a disruptive innovation for malaria testing – the Urine Malaria Test (UMT) – the first and only non-blood test that tells if a fever is due to malaria, using a few drops of urine. The UMT changes the cost equation and user experience in malaria testing globally, driving a move away from health facility-based care approach to home- or individual user-based malaria testing model, similar to home pregnancy testing and blood sugar testing for diabetes patients. With the UMT, it is now possible for anyone, anywhere, to rapidly and conveniently test for malaria – no blood, no reagent, no equipment.
Our products pipeline includes other non-blood tests for common febrile illnesses in emerging markets.